🇺🇸 FDA
Pipeline program

Pembrolizumab (K)

3475-756

Phase 3 mab active

Quick answer

Pembrolizumab (K) for Breast Cancer is a Phase 3 program (mab) at Merck KGaA, Darmstadt, Germany with 1 ClinicalTrials.gov record(s).

Program details

Company
Merck KGaA, Darmstadt, Germany
Indication
Breast Cancer
Phase
Phase 3
Modality
mab
Status
active

Clinical trials